Traders Purchase High Volume of Revolution Medicines Put Options (NASDAQ:RVMD)

Revolution Medicines, Inc. (NASDAQ:RVMD) saw unusually large options trading on Friday. Investors bought 12,797 put options on the company. This represents an increase of approximately 131% compared to the average daily volume of 5,546 put options.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Large institutional interest — several big funds (General Atlantic, Norges Bank, Avoro, UBS, Polar Capital) have taken or increased stakes recently, which signals strong institutional conviction and can provide buying support. MarketBeat Institutional/Insider Summary
• Positive Sentiment: Analyst tone is largely favorable — multiple upgrades/initiations and a consensus “Buy” bias underpin positive sentiment among investors and can stabilize demand. Analyst Coverage Summary
• Neutral Sentiment: Company profile and pipeline are long-term positives but carry standard biotech clinical/readout risk — lead programs include RMC‑4630 (SHP2), RMC‑6291 (KRAS G12C) and RMC‑6236 (pan‑RAS).
• Neutral Sentiment: Recent results (Feb. 25) showed a wider-than-expected quarterly loss (EPS -$1.86 vs. -$1.56 est.), a reminder of ongoing cash burn and negative EPS guidance for the year — a typical headwind for development-stage biotechs. Earnings Summary
• Negative Sentiment: Unusual options activity — investors bought 12,797 put contracts (a ~131% increase vs. average put volume of 5,546), a bearish flow that can amplify near‑term downside and volatility.
• Negative Sentiment: Cluster of insider sales on Mar. 17 — several senior insiders trimmed positions (Mark A. Goldsmith 12,871 shares; Margaret A. Horn 4,583; Stephen M. Kelsey 4,302; Jack Anders 2,753; Lin Wei 2,073; Xiaolin Wang 2,010). Multiple Form 4 filings were submitted to the SEC, which can be interpreted negatively by some investors even if sales are for diversification or routine reasons. SEC filings: Read More. · Read More. · Read More. · Read More. · Read More. · Read More.

Insider Activity at Revolution Medicines

In related news, insider Mark A. Goldsmith sold 12,871 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $1,280,407.08. Following the completion of the transaction, the insider directly owned 276,698 shares of the company’s stock, valued at $27,525,917.04. This trade represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Xiaolin Wang sold 2,010 shares of Revolution Medicines stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $199,954.80. Following the sale, the insider owned 116,063 shares in the company, valued at $11,545,947.24. This represents a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 149,592 shares of company stock worth $15,010,732 in the last three months. Company insiders own 8.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. General Atlantic L.P. bought a new stake in shares of Revolution Medicines during the third quarter worth $115,556,000. Norges Bank acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at $195,568,000. Avoro Capital Advisors LLC bought a new position in shares of Revolution Medicines in the fourth quarter valued at about $172,840,000. UBS Group AG raised its holdings in shares of Revolution Medicines by 183.6% in the fourth quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock valued at $245,954,000 after buying an additional 1,998,972 shares during the last quarter. Finally, Polar Capital Holdings Plc lifted its position in Revolution Medicines by 321.2% during the 4th quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock worth $160,398,000 after buying an additional 1,535,686 shares in the last quarter. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Stock Down 3.5%

RVMD opened at $95.78 on Friday. The firm’s 50-day simple moving average is $102.96 and its 200-day simple moving average is $76.81. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14. Revolution Medicines has a twelve month low of $29.17 and a twelve month high of $124.49. The firm has a market cap of $18.98 billion, a price-to-earnings ratio of -16.21 and a beta of 0.99.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter in the previous year, the company earned ($1.12) EPS. Equities research analysts anticipate that Revolution Medicines will post -3.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RVMD has been the subject of a number of analyst reports. Evercore raised shares of Revolution Medicines to a “strong-buy” rating in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. Jefferies Financial Group initiated coverage on shares of Revolution Medicines in a research report on Monday, March 16th. They issued a “buy” rating for the company. Benchmark restated an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a report on Friday, January 9th. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.